title: Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.
abstract: : Molecularly targeted cancer therapy has rapidly changed the landscape of oncologic care, often improving patients' prognosis without causing as substantial a quality-of-life decrement as cytotoxic chemotherapy does. Nevertheless, targeted agents can cause side effects that may be less familiar to medical oncologists and that require the attention and expertise of subspecialists. In this review, we focus on hyperglycemia, which can occur with use of new anticancer agents that interact with cell proliferation pathways. Key mediators of these pathways include the tyrosine kinase receptors insulin growth factor receptor 1 (IGF-1R) and epidermal growth factor receptor (EGFR), as well as intracellular signaling molecules phosphatidylinositol 3-kinase (PI3K), AKT, and mammalian target of rapamycin (mTOR). We summarize available information on hyperglycemia associated with agents that inhibit these molecules within the larger context of adverse event profiles. The highest incidence of hyperglycemia is observed with inhibition of IGF-1R or mTOR, and although the incidence is lower with PI3K, AKT, and EGFR inhibitors, hyperglycemia is still a common adverse event. Given the interrelationships between the IGF-1R and cell proliferation pathways, it is important for oncologists to understand the etiology of hyperglycemia caused by anticancer agents that target those pathways. We also discuss monitoring and management approaches for treatment-related hyperglycemia for some of these agents, with a focus on our experience during the clinical development of the EGFR inhibitor rociletinib.
  
  
  CONCLUSIONS
  Treatment-related hyperglycemia is associated with several anticancer agents. Many cancer patients may also have preexisting or undiagnosed diabetes or glucose intolerance. Screening can identify patients at risk for hyperglycemia before treatment with these agents. Proper monitoring and management of symptoms, including lifestyle changes and pharmacologic intervention, may allow patients to continue benefiting from use of anticancer agents.
authors.affiliation: Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Santa Monica, California, USA jwgoldman@mednet.ucla.edu.
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Goldman
authors.affiliation: Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Santa Monica, California, USA.
authors.forename: Melody A
authors.initials: MA
authors.lastname: Mendenhall
authors.affiliation: Endocrinology Medical Group of Orange County, Inc., Orange, California, USA.
authors.forename: Sarah R
authors.initials: SR
authors.lastname: Rettinger
keywords: Anticancer agents; Growth factor; Molecular targeted therapy; Proto-oncogene protein Akt; Receptors; Tyrosine kinase; mTOR protein